Covis Pharma to Acquire US Rights from Sanofi for Nilandron®, Plaquenil®, Rilutek®, Uroxatral®, and Kayexalate®

  Covis Pharma to Acquire US Rights from Sanofi for Nilandron®, Plaquenil®,
                    Rilutek®, Uroxatral®, and Kayexalate®

PR Newswire

ZUG, Switzerland, April 4, 2013

ZUG, Switzerland, April 4, 2013 /PRNewswire/ --Covis Pharma Sarl ("Covis
Pharma"), a Switzerland-based specialty pharmaceutical company today announced
an agreement with sanofi-aventis U.S. LLC and certain of its affiliates
("Sanofi") to acquire full commercial rights for Nilandron® (nilutamide),
Plaquenil® (hydroxychloroquine), Rilutek® (riluzole), Uroxatral® (alfuzosin
hydrochloride), and Kayexalate® (sodium polystyrene sulfate) in the United
States. The aggregate sales for these products in the United States in 2012
were $114.6 million. Sanofi will retain the existing rights for these
products in countries outside the United States. Terms of the agreement have
not been disclosed.

"We are very pleased to announce the addition of these products to our
existing portfolio," said Jack Davis, CEO of Covis Pharma. "Covis will
continue to supply consistent, top quality, branded pharmaceuticals, ensuring
that patients receive the therapeutic care they need." Covis Pharma will
promote these branded products through its US-based distributor, Covis
Pharmaceuticals Inc. Covis Pharma also supplies authorized generic products
to the US market through a separate distributor, Rising Pharmaceuticals Inc.
Sanofi will manufacture and supply the products for Covis Pharma.

The agreement has received Hart-Scott-Rodino regulatory clearance in the
United States.

About Covis Pharma

Headquartered in Zug, Switzerland, Covis Pharma is a global specialty
pharmaceutical company providing therapeutic solutions to patients. The
company's distinctive product portfolio addresses life threatening and other
serious medical conditions. With eleven branded products currently in market,
Covis Pharma aims to become a leading specialty pharmaceutical company through
organic, as well as global acquisitive, growth. The investor group in Covis
Pharma has significant investment and operational experience in the specialty
pharmaceutical industry. Led by affiliates of Cerberus Capital Management,
L.P., one of the world's leading private investment firms, the investor group
also includes Princeton Biopharma Capital Partners, LLC and Bourne
Partners.For more information, visit 


Covis Pharma, 212-891-1558,

SOURCE Covis Pharma

Press spacebar to pause and continue. Press esc to stop.